Today we begin a weekly post of the table of contents for the current issue of "The Tan Sheet." As often as we refer to previous stories we've reported related to news items in our blog, we decided the natural next step is to let you know what we've reported in our current issue.
Plavix Stomach Drug Interactions Upset Heartburn Market
An FDA warning that people prescribed Plavix (clopidogrel) should not take specific heartburn drugs creates a significant opportunity for other OTC products in the category "to make some hay," a marketing consultant says.
Co-Packaging Enters Gray Area As Option For OTC/Supplement Combos
Experts disagree whether creative co-packaging of OTC drugs and dietary supplements is a legitimate alternative to problematic combination products or simply another regulatory quagmire.
Mead Johnson Likely To Draw Suitors Following BMS Split
Mead Johnson's impending split-off from Bristol-Myers Squibb, announced Nov. 16, makes the rapidly growing nutritional company an appealing acquisition target for the back half of 2010, analysts predict.
REGULATORY
- Inconsistencies "Complicate" Food Supply-Chain Tracing - Report
- Senate Exempts Supplements From Redundant Regs, Suppliers Left Hanging
OTCSs
- Chart: OTC Heartburn Products Market Shares
FDA
- FDA Expands Drug Center Leadership With Temple, Throckmorton Promotions
- FDA To Address Industry Questions In Transparency Effort
DIETARY SUPPLEMENTS
- SupplySide West New Products In Brief
- FDA's Frankos Grades GMP Complaint Recordkeeping "Needs Improvement"
PEOPLE
- People In Brief
- Pharma Industry Watchdog Brill Nominated For FTC Commissioner
IN BRIEF
- FDA seeks comments on nutrition facts study, food survey
- FTC warning letters
- Tricare extends OTC demo
- FDA recalls tainted supplements
- NACDS offers platform for CPSIA certification
- Vicks Sinex recalls in U.S., Europe
- Groups request DRI for omega-3s
- SupplySide attracts healthy attendance
- Santarus expects Rx gains from OTC Zegerid
(Not a subscriber to "The Tan Sheet"? Click here for a free trial.)
-- Malcolm Spicer (m.spicer@elsevier.com)
